MTCR Metacrine, Inc.

Metacrine is a clinical-stage biopharmaceutical company building a potentially best-in-class pipeline of drugs to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as a potential new treatment for non-alcoholic steatohepatitis (NASH).

As of 11/30/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/16/2020
Outstanding shares:  27,314,553
Average volume:  1,875,606
Market cap:   $35,782,064
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    59101E103
ISIN:        US59101E1038
Valuation   (See tab for details)
PE ratio:   -2.24
PB ratio:   0.72
PS ratio:   0.00
Return on equity:   -126.26%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy